Comparison of the Efficacy and Safety between Transradial and Transfemoral Percutaneous Coronary Intervention in Patients with Ischemic Heart Disease.
- Author:
Min Gyu KONG
1
;
Hye Young JU
;
Seok Chun YEUM
;
Jin Woo CHOO
;
Dae Chul SEO
;
In Ki MOON
;
Jin Nyoung KIM
;
Ho Eun JUNG
;
Yun Ju CHO
;
Byoung Won PARK
;
Jin Wook CHUNG
;
Duk Won BANG
;
Min Su HYON
Author Information
1. Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. mshyon@schmc.ac.kr
- Publication Type:Original Article
- Keywords:
Radial artery;
Femoral artery;
Coronary artery disease;
Complications
- MeSH:
Aneurysm, False;
Arteriovenous Fistula;
Coronary Artery Disease;
Femoral Artery;
Follow-Up Studies;
Heart;
Hematoma;
Humans;
Medical Records;
Myocardial Infarction;
Myocardial Ischemia;
Percutaneous Coronary Intervention;
Radial Artery;
Retrospective Studies;
Stents;
Stroke;
Thrombosis
- From:Soonchunhyang Medical Science
2012;18(2):81-84
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of transradial percutaneous coronary intervention (TRI) compared with transfemoral percutaneous coronary intervention (TFI) in patients with ischemic heart disease. METHODS: We reviewed retrospectively the medical records including imaging data of the patients with ischemic heart disease who underwent TRI or TFI from January 2007 to December 2009 in Soonchunhyang University Seoul Hospital. We compared major adverse cardiac and cerebrovascular events (MACCEs) including death, myocardial infarction, revascularization, stent thrombosis, and cerebrovascular accident during follow-up period. We also compared procedure related vascular complications including hematoma, arteriovenous fistula, pseudoaneurysm, and infection. RESULTS: Total number of patients was 347 (256 patients of TRI and 91 patients of TFI). There were no significant differences in the rate of MACCEs between two groups. There were significantly less procedure-related vascular complications in TRI group (3.1% vs. 11.0%, P=0.010). CONCLUSION: TRI is as effective as TFI with no difference in the rate of MACCEs in patients with ischemic heart disease. TRI is superior to TFI in safety with reduction of vascular complications.
